β Scribed by Arnold L. Demain
No coin nor oath required. For personal study only.
For more than 50 years, natural products have served us well in combating infectious bacteria and fungi. Microbial and plant secondary metabolites helped to double our life span during the 20th century, reduced pain and suffering, and revolutionized medicine. Most antibiotics are either (i) natural products of microorganisms, (ii) semiβsynthetically produced from natural products, or (iii) chemically synthesized based on the structure of the natural products. Production of antibiotics began with penicillin in the late 1940s and proceeded with great success until the 1970β1980s when it became harder and harder to discover new and useful products. Furthermore, resistance development in pathogens became a major problem, which is still with us today. In addition, new pathogens are continually emerging and there are still bacteria that are not eliminated by any antibiotic, e.g., Pseudomonas aeruginosa. In addition to these problems, many of the major pharmaceutical companies have abandoned the antibiotic field, leaving much of the discovery efforts to small companies, new companies, and the biotechnology industries. Despite these problems, development of new antibiotics has continued, albeit at a much lower pace than in the last century. We have seen the (i) appearance of newly discovered antibiotics (e.g., candins), (ii) development of old but unutilized antibiotics (e.g., daptomycin), (iii) production of new semiβsynthetic versions of old antibiotics (e.g., glycylcyclines, streptogrammins), as well as the (iv) very useful application of old but underutilized antibiotics (e.g., teicoplanin). Β© 2009 Wiley Periodicals, Inc. Med Res Rev, 29, No. 6, 821β842, 2009
π SIMILAR VOLUMES
## Abstract Physiological consequences resulting from proteinβbound Maillard compounds in foods must be discussed carefully. This was the idea behind the debate, which is put for discussion by the papers by Sebekova and Somoza, who argued for the motion that dietary advanced glycation end products
We have established three hybridoma cell lines (designated EBI-1, -2, and -3) secreting immunoglobulin C (IgG) antibodies specific for human alpha-interferon (HulFN-a) by fusing P3X63Ag8.6.5.3 myeloma cells with spleen cells of mice immunized with human "lymphoblastoid" (NC-37) interferon (IFN). The
## FOR ACQUIRED RESISTANCE OF HUMAN A375 MELANOMA The proliferation of human melanoma cell line A375-6 is inhibited by interleukin I (IL-I). However, the cells acquired resistance to IL-I after a long period of culture. We have reported that 2 resistant subclones, A375-R8 and -R19, produced ILla c